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Abstract
HIV-1 variants that show unusual sensitivity to autologous antibodies due to presence of critical neutralization signatures
would likely contribute towards rational envelope based HIV-1 vaccine design. In the present study, we found that presence
of a naturally occurring H681 in gp41 membrane proximal external region (MPER) of a clade C envelope (Env) obtained from
a recently infected Indian patient conferred increased sensitivity to autologous and heterologous plasma antibodies.
Furthermore, Env-pseudotyped viruses expressing H681 showed increased sensitivity to soluble CD4, b12 and 4E10
monoclonal antibodies both in related and unrelated Envs and was corroborated with increased Env susceptibility and
binding to cellular CD4 as well as with prolonged exposure of MPER epitopes. The increased gp120-CD4 interaction was
further associated with relative exposure of CD4-induced epitopes and macrophage infectivity. In summary, our data
indicate that Y681H substitution exposes neutralizing epitopes in CD4bs and MPER towards comprehensive interference in
HIV-1 entry.
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Introduction
It is widely believed that a successful and protective vaccine to
Human Immunodeficiency virus Type 1 (HIV-1) will lie in its
ability to induce broadly neutralizing antibody (NAb) response [1].
Though infection with HIV-1 results in antibody response to most
viral proteins, but only antibodies to the surface envelope (Env) are
capable of mediating virus neutralization and restrict entry [2,3].
Thus, identification of signatures in Env that optimally exposes
epitopes that are targets of broadly neutralizing antibodies are
highly sought [4].The HIV-1 Env is heavily glycosylated and
composed of three identical surface gp120 monomers, each non-
covalently associated with a transmembrane gp41 molecule
[2,5,6]. These trimeric Env spikes are responsible for interacting
with cell surface CD4 and a coreceptor to initiate viral entry. It is
believed that the binding of NAbs to native gp120 trimers is
necessary for efficient neutralization [7]. However, the inherent
instability of the HIV-1 envelope (Env) spikes has presented
challenges to the development of native recombinant trimers [8].
This suggests that the ability of neutralizing antibodies (NAbs) in
abrogating HIV-1 entry is dependent on conformational stability
of gp120 required for optimum CD4 binding and/or interfering
fusion of viral and cellular membrane mediated by gp41. Although
antibodies targeting gp41 and gp120 variable regions is detected as
early as three weeks after infection [9,10], detectable NAbs against
the viral Env are usually generated only after several months of
infection [11]. Importantly, the early NAb response is subsided by
successive escape of virus from autologous antibodies
[12,13,14,15,16,17] for continued high-level of virus replication
towards progressive destruction of CD4
+ T cells, development of
acquired immunodeficiency syndrome (AIDS).
Env has a complex structure and upon gp120 engagement with
CD4 receptor it undergoes substantial rearrangements in its
conformation that facilitates virus fusion with host cell [18,19,20].
The precise mechanism of how Env in the CD4-bound
configuration undergoes conformational changes is not understood
clearly, however it is generally believed that the conformational
switch of Env from the unliganded to the CD4-bound state is
probably modulated by topological layers present in the inner
domain of gp120 that are believed to be flexible in nature [21].
Finzi et al [21] recently demonstrated that, as CD4 comes in
contact with the Env outer domain, the topological layers 1 and 2
interact in such a way that this resulted in strengthening gp120-
CD4 interaction. Although HIV-1 Env is the principal target for
NAbs and neutralizing epitopes are present in both Env subunits
[22], several targets in Env vulnerable to antibody neutralization
are not present on the trimeric form of virion-associated Env, such
as V3 loop, CD4-induced epitopes (CD4i) and CD4 binding site
(CD4bs) [23,24,25]. Despite this variations in presentation of
neutralizing epitopes, patients have been shown to develop robust
NAb titers to their autologous antibodies [26,27,28,29,30]. It is of
interest that due to fitness constraints some viruses do not undergo
rapid evolution and thus become significantly less resistant to
neutralization [13,31,32] and as such certain epitopes on Env
present in these viruses remain vulnerable to neutralizing
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irrespective of virus evolution under immense humoral pressure
and are targets of broad and potent neutralizing antibodies such as
the newly discovered monoclonal antibodies (MAbs) that targets
CD4bs and quaternary epitopes (QNE) [32,33,34] are of
particular interest and could potentially contribute towards a
successful vaccine development. Some of these epitopes are well
studied, while others like those present on variable loops for newly
discovered broadly neutralizing monoclonal antibodies (bNAbs
such as PG9 and PG16 [34,35,36] are being studied in depth
[11,37,38]. In addition to sites on gp120, the membrane proximal
external region (MPER) of gp41 that is formed by a linear
sequence of 30 amino acids is vulnerable to NAbs [11]. MPER in
gp41 is the target of three known neutralizing monoclonal
antibodies (MAbs); 2F5, 4E10, and Z13e (34–36), although few
others have been described recently [39,40]. Antibodies that bind
to the MPER are believed to block viral fusion to the host cell
membrane, and thus abrogate viral entry (59). Though these
MAbs, especially 4E10 targeting MPER have shown remarkable
breadth, they appear to be uncommon during natural infection
(40, 60–62). Interestingly, viruses that escape the autologous serum
NAb response has been shown to generally remain sensitive to
neutralization by b12, 2G12, and the MPER-directed MAbs
suggesting that the initial NAb response is least likely directed to
these more conserved epitopes on gp120 [11]. The MAbs 2F5 and
4E10 have been shown to be unusually hydrophobic and auto
reactive [41,42] due to which these antibodies possibly face
problems in gaining easy access to conserved regions of HIV-1
during natural infection. Very recently, it was shown that residues
in gp41 modulated neutralization sensitivity of HIV-1 Env [43,44],
suggesting that gp41 with relatively highly conserved sequences
than that of gp120 may provide better targets for comprehensive
virus neutralization. Recently, we showed that a single amino acid
substitution (I424M) in C4 region of gp120 exposed vulnerable
neutralizing epitopes in CD4bs and V3 loop in a clade C Env [45]
obtained from an Indian patient (IVC-4) with recent infection
[46]. In the present study, we examined the basis of enhanced
sensitivity of one env clone to autologous plasma antibodies
compared to the contemporaneous env clones amplified simulta-
neously at the base line visit from the same patient (IVC-4) [46].
On further investigation, we found that a single Y681H
substitution in the gp41 MPER conferred increased sensitivity of
Env-pseudotyped viruses to antibodies targeting CD4bs and
MPER and was associated with increased macrophage infectivity.
Results
A single Y681H substitution in gp41 conferred enhanced
Env sensitivity to autologous and heterologous plasma
antibodies
We previously described [46] two clade C Env clones 4.J2 and
4.J22 obtained from a recently infected Indian patient at the
baseline (at the same time point) which differed in their sensitivities
to autologous plasma antibodies (ID50 of 4.J2=1:540 against ID50
of 4.J22,100) (Figure 1A). The Env clones obtained were within
one year of infection as determined by detuned ELISA as
described earlier [46]. Sequence comparison between these two
Envs revealed differences of altogether six residues in gp160, two
in V1V2 domain (at positions 148 and 174 respectively) of gp120
and four in gp41 (Figure 1B). Out of the four residues that differed
between these two Envs in gp41 domain, two were in the MPER
region at positions 668 and 681, while the two others were at
positions 551 and 839. We first investigated domains in Env that
modulated sensitivity to contemporaneous autologous plasma by
constructing Env chimeras between 4.J2 and 4.J22. Pseudotyped
viruses carrying chimeric Env constructs were tested for their
neutralization sensitivity to autologous contemporaneous plasma
antibodies. As shown in Figure 2, as opposed to the wild type, 4.J2
containing gp41 grafted from 4.J22 conferred resistance while
4.J22 containing gp41 from 4.J2 became sensitive to autologous
antibodies, indicating that gp41 in these Envs conferred altered
sensitivities to autologous plasma antibodies in this patient. Since
residues at positions 668 and 681 in these Envs were within
MPER, a region of effective target of neutralizing antibodies, and
in very close proximities to motifs that are targets of 2F5 and
4E10, we substituted N668S and H681Y (668S and 681Y were
present in resistant Env 4.J22) in the sensitive 4.J2 Env and tested
against autologous plasma antibodies. As shown in Figure 2, we
found that while 4.J2 (N668S) retained similar sensitivity to
autologous plasma as 4.J2, 4.J2 (H681Y) became resistant,
suggesting that Y681 was responsible for neutralization resistance
of 4.J22 Env clone in this patient. Interestingly, when tested
against heterologous plasma antibodies obtained from five
chronically infected patients, 4.J2 (containing H681) showed
increased sensitivity while 4.J2 (H681Y) was found to be resistant
(Figure 2). Our data indicated that H681 enhanced neutralization
possibly by altering Env conformations.
Figure 1. Construction of chimeric envelopes. Chimeric Envs were
constructed by swapping of gp120 and gp41 between sensitive (4.J2)
and resistant (4.J22) patient Envs using NotI, BbvCI and HindIII
restriction enzymes. The ID50 values of pseudotyped viruses carrying
4.J2, 4.J22 and 4.J27 Envs to autologous plasma reported earlier [46]
were shown on top; highlighted column represents ID50 of Env-
pseudotyped viruses to contemporaneous plasma at the base line.
doi:10.1371/journal.pone.0037157.g001
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Since H681 was located in MPER, to further examine if
resistance to autologous neutralization conferred by H681Y was
due to its effect on MPER, we tested the sensitivity of
pseudoviruses carrying 4.J2 (H681) and 4.J2 (Y681) Envs to
4E10 MAb. We did not test the sensitivities of these Envs to 2F5 as
they were found to be resistant to 2F5 because of lack of minimum
DKW motif for 2F5 recognition [46]. As shown in Figure 3A, we
found that while 4.J2 (N668S) did not alter 4E10 sensitivity,
H681Y conferred 4E10 resistance by greater than 16-folds.
Enhancement of Env sensitivity to 2F5 was also found with
unrelated Envs with Y681H substitutions (Table 1), although it
was not as dramatic as 4E10. Our data indicated that presence of
H681 modulated Env conformation at MPER and increased
neutralization by antibodies targeting this region.
Since 4E10 MAb targets the structural intermediate formed
during the fusion process we further explored if increased
sensitivity of Envs to antibodies targeting MPER in presence of
H681 was due to alteration in fusion kinetics. Hence, we tested the
sensitivities of Envs with both Y681 and H681 to T20, a classical
fusion inhibitor that inhibits 6-helix bundle formation and prevent
fusion, at different doses. As shown in Table 1, Y681H indeed
exhibited enhanced inhibition of Envs by T20 in a dose-dependent
manner (Figure S1). Statistical analysis of paired IC50 values
(H681 versus Y681) by one tailed t-test showed significant increase
in sensitivity of H681 Env variants to T20 (P=0.04), suggesting
that presence of H681 indeed interfered with fusion efficiency and
likely resulted in altered exposure of neutralizing epitopes in
MPER. Since differences in T20 sensitivities by Envs indicated
altered kinetics of structural transition of gp41 during fusion due to
Y681H substitution, we further examined if this phenomenon
leads to differences in exposure of MPER. To test this we carried
out virus–cell post-attachment neutralization assay using 4E10
MAb as described recently [44] and measured the infectivity of
pseudoviruses 4.J2 (H681) and 4.J2 (Y681) as a function of time of
addition of 4E10 MAb. Briefly, Env-pseudotyped viruses were
adsorbed in TZM-bl cells on ice for 2 hours. Subsequently,
unbound viruses were removed by successive washing with cold
medium. To examine how 4E10 MAb arrests virus fusion with
TZM-bl cells, 4E10 MAb (10 mg/ml) was added to TZM-bl cells
pre-adsorbed with Env-pseudotyped viruses at different time
intervals. As shown in Figure 3B, we found that while 4E10
neutralization of 4.J2 Env (containing H681) was prolonged and
was effective up to 15 minutes post-attachment, presence of Y681
rendered 4.J2 (H681Y) with rapid fusion (within 5 minutes).
Sensitivity to T20 and time course of 4E10 neutralization, taken
together, suggested that slower entry of virus into the cell possibly
due to altered fusion kinetics upon Y681H substitution leading to
prolonged exposure of MPER epitopes.
Effect of Y681H substitution on CD4 binding sites in
gp120
Neutralization of wild type Envs 4.J2 (containing N668, H681)
and 4.J22 (containing S668, Y681) with soluble CD4 showed that
4.J2 was sensitive while 4.J22 being completely resistant at 25 mg/
ml. Next we wanted to know what domain has modulated this
sensitivity to sCD4. We assessed the neutralization sensitivity of
Figure 2. Neutralization of patient Envs by autologous and heterologous plasma antibodies. A. Neutralization curves of Env-
pseudotyped viruses carrying chimeric Envs as well as with point substitutions at positions 668 and 681 were tested against autologous plasma
antibodies. Percent neutralization at various dilutions of plasma is plotted and compared with virus control (VC) where growth medium was used
instead of plasma. Note that the gp41 has modulated the neutralization sensitivity to autologous plasma and specifically H681Y substitution in 4.J2
Env was found to associate with reduced neutralization sensitivity to autologous plasma. B. 4.J2 Env carrying H681 was found to confer enhanced
sensitivity to HIV-1
+ heterologous plasma samples (CR2, CR3, CR5, LT1, LT3) while Y681 rendered significant reduction of 4.J2 Env sensitivity to same
heterologous plasma samples. Plasma pool represents the mixture of above five plasma specimens. The neutralization assays were done in duplicate
and in at least three independent experiments. In all cases, VC stands for virus control where plasma was not added and thus considered as 0%
neutralization.
doi:10.1371/journal.pone.0037157.g002
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4.J2 where we substituted H681Y and N668S, and wild type Envs.
As shown in Figure 4A, 4.J2 (H681) conferred significantly higher
sensitivity to sCD4 over 4.J2 (Y681) by .40-folds, N668S
moderately decreased the sensitivity to sCD4. All the Envs which
contained H681 showed higher sensitivity to sCD4 in the panel of
Envs while those containing Y681 were completely resistant at
10 mg/ml. This data shows that N668 and H681 act in
cooperation to enhance the sensitivity of Env to sCD4, although
H681 exerts more influence than N668 for sensitivity. The results
were quite intriguing as the same H681 which modulated the
neutralization sensitivity to 4E10 was found to alter sCD4
sensitivity-the phenotype which is supposedly more relevant to
changes in gp120. The data imply that the change in MPER does
not only exert its effect at local site in gp41 subunit but also
traverse through transmembrane subunit to surface protein gp120
to alter the conformation at CD4 binding site as supported by
CD4-Ig and IgG1b12 binding with Env trimers (Figure 5).
To elucidate the cause of enhanced neutralization of H681
variants by sCD4 we carried out Env-anti-CD4 antibody
competition assay with TZM-bl cells that express CD4 and
CCR5. This assay aimed to measure the binding affinity of Envs
(with H681 or Y681) with CD4 expressed on the TZM-bl cells. In
this assay, equal quantity of virus was resuspended in various
dilutions of anti-CD4 antibody and added on the TZM-bl cells in
96 well tissue culture plate and the infectivity was measured after
48 hours of incubation by measuring luciferase activity. The data
showed that as the concentration of anti-CD4 antibody (QS1420)
reduced the infectivity of 4.J2 (H681) increased rapidly as
compared to 4.J2 (Y681). As shown in Figure 4B, the rate of
increase in infectivity of 4.J2 (H681) was found to be ,5 times
higher than 4.J2 (Y681). Similar results were observed with Y681
and H681 versions of YU2 although the difference in affinity of
these two was subtle. The subtle increase in affinity of YU2 (H681)
might be because intrinsic high sensitivity of YU2 wild type to
sCD4 and IgG1b12 and though difference in neutralization
sensitivity of H681 and Y681 is apparent the difference in affinity
is marginal.
Effect of Y681H substitution on interaction of IgG1b12
and CD4-Ig with Env trimers. Next we examined whether
there was any association between enhanced neutralization
sensitivity due to presence of H681 with increased binding of
CD4-Ig and IgG1b12 MAb to Env trimers expressed on the cell
surface in cell-based ELISA (CELISA) as described recently [47].
Thus, we examined H681 and Y681 versions in 4.J2, YU2 and
CRF02-AG235 Envs that showed enhanced sensitivity to sCD4 for
their degree of relative binding to Env trimers expressed on 293T
cells. The 4.J2 Envs were not tested against IgG1b12 as they were
known to be resistant to this MAb [46]. For both CD4-Ig and
IgG1b12, all the Envs expressing H681 showed (Figure 5)
significant increase (P,0.05) in their binding relative to those
expressing Y681; although YU2 (H681) showed marginal increase
in CD4-Ig binding compared to that of Y681, it was not significant
(P=0.15). Although the direct evidence of conformational change
is lacking, mounting data from the binding and neutralization
assays with reagents that interfered the Env: CD4 interaction
suggested that Y681H substitution indirectly altered the Env
conformation at CD4 binding site and favors the interaction of
Env with these reagents.
Y681H substitution enhances infectivity in low CD4
expressing cells
Since Envs expressing H681 showed enhanced sensitivity to
sCD4 (Figure 4) and IgG1b12 (Table 1) and showed relatively
increased binding with CD4-Ig and b12 over Envs expressing
Y681, we hypothesized that H681 possibly modulated Env
conformation at CD4 binding site in gp120. The enhanced
Figure 3. Effect of Y681H substitution on exposure of neutralizing epitopes in gp41 MPER. A. Neutralization sensitivity of Env-
pseudotyped viruses expressing Y681 and H681 were tested against 4E10 MAb in TZM-bl cells. Percent neutralization on Y-axis against serial dilutions
of 4E10 indicated on X-axis shows H681 conferring increased Env sensitivity to 4E10 MAb (and also T20; see Figure S1 and Table 1). The neutralization
assays were done in duplicate in more than three independent experiments. VC stands for virus control where antibody was not added. B. Time
course of 4E10 MAb neutralization of Envs. 4E10 was added in warm condition (37uC) at different time points in TZM-bl cells which were pre-
adsorbed with Env pseudotyped virus in cold condition. The percent infection is plotted on Y-axis against various time points of 4E10 addition given
on X-axis. No 4E10 indicates infection of TZM-bl cells in absence of 4E10 MAb and hence serves as virus control. Note that 4E10 could neutralize 4.J2
(H681) by 50% up to 6 min as opposed to 1 min for 4.J2 (Y681). TND S669 that was earlier reported [44] for enhanced exposure of neutralizing
epitopes in MPER was used as positive control.
doi:10.1371/journal.pone.0037157.g003
Y681H Confers Enhanced HIV-1 Neutralization
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Y681H substitution likely induced exposure of CD4bs enabling
Envs towards low CD4 dependence for productive entry into the
target cells. Thus, to test this, we examined the effect of N668S
and H681Y on CD4 dependence of these Envs by infecting Env-
pseudotyped viruses carrying both H681 and Y681 in HeLa cells
expressing low CD4 but high CCR5 (Clone RC49) [48]. RC49
cells express high amount of CCR5 coreceptor but limiting
amount of CD4 and virus infectivity in these cells is a measure of
CD4 dependence of Env for entry. As expected, we found that 4.J2
(H681) showed greater infectivity in RC49 cells (Figure 6A) than
4.J2 (Y681) indicating that H681 modulated Env towards greater
CD4bs exposure and possibly enhanced binding with CD4. In
comparison to H681Y, N668S substitution in 4.J2 Env showed
only modest reduction in infectivity of RC49 cells, suggesting
H681 predominantly affected CD4bs in Env. Finally, we
examined the effect of increased exposure of CD4bs due to
presence of H681 in Env-pseudotyped viruses on their degree of
infectivity in monocyte-derived macrophages (MDM) (obtained
from three different donors) that naturally express low amounts of
cell surface CD4 [49,50]. Thus, MDMs were infected with equal
TZM-bl infectious units of 4.J2 (H681) and 4.J2 (Y681) and
infectivity measured by immunostaining of p24 positive cells as
described before [51]. As shown in Figure 6B and C, 4.J2
expressing H681 showed significant enhanced infectivity in
macrophages (P,0.05) compared to 4.J2 expressing Y681. In this
assay, YU2 and JR-CSF Envs were used as positive and negative
controls respectively [52]. Our data indicated that H681
modulated overall Env conformation that is more suitable for
CD4 interaction and thus enhanced infectivity in low CD4
expressing cells.
The enhanced neutralization of H681 Envs over Y681 Envs by
autologous and heterologous plasma pool led to the consideration
of possibility that Y681H substitution might act on coreceptor
binding site (CoRbs) and shift Env trimer to its open form
mimicking CD4 bound state of gp160. Previous studies [53,54]
have showed that Env which exposes CoRbs in unbound state or
the Envs which are independent of CD4 are extremely sensitive to
antibodies. Thus, to test whether presence of H681 modulated
exposure of CoRbs in Env, we examined the sensitivity of Envs
expressing H681 and Y681 against 17b (that binds to CD4-
induced epitope). Neutralization data (Figure S2) with 4.J2 and
YU2 Envs showed enhanced sensitivity of H681 variants to 17b by
.4 and .3 fold respectively (P,0.0001) suggesting that Y681H
substitution essentially exposed CoRbs that is more reactive
structure for binding with CD4 but more sensitive to neutraliza-
tion.
Y681H substitution displayed enhanced neutralization in
unrelated Envs
In the present study, we examined whether introduction of
H681 in place of much conserved Y681 in autologous and
unrelated Envs (both clade C and non-clade C Envs) results in
similar enhancement of Env sensitivity to neutralizing antibodies
Table 1. Neutralization properties of Envs carrying Y681 and H681 in different genetic backgrounds.
IC50 (mg/ml)
Envs Clade b12 sCD4 4E10 2F5 T20
Pooled Plasma
(Reciprocal
Dilutions)
4.J2 C .25 0.625 0.28 No motif { 0.0054 1011
4.J2 (H681Y) C .25 .25 (.40*) 4.2 (15) No motif 0.008 102 (9.9*)
11-3.J3 C .25 .25 5.64 .25 0.2 443
11-3.J3 (Y681H) C .25 4.49 (.6*) 1.76 (3.2*) 12.5 (.2*) 0.015 (13.33*) 8266 (18.65*)
2-3.J7 C2 . 2 .25 6.0 No motif{ 0.165 161
2-3.J7 (Y681H) C 0.31 (8.8*) 4.5 (.6*) 1.3 (4.6*) No motif 0.0353 (4.67*) 354 (2.2*)
YU2 B 3.5 1.1 25 .25 0.9 134
YU2 (Y681H) B 0.25 (14*) ,0.078 (.15*) 0.83 (30.1*) 1.86 (.14*) 0.09 (10*) 418 (3.12*)
Q259ENVd2.17 A .25 .25 .25 .25 0.50 82
Q259ENVd2.17 (Y681H) A 6.74 (.4*) 6.85 (.4*) 1.76 (.14*) .25 (none) 0.02 (25*) 128 (1.56*)
0.0078 105
CRF-02_AG-235 A/G .25 .25 4.1 .25 0.0039 (2*) 930 (8.85*)
CRF-02_AG-235 (Y681H) A/G 0.83 (.30*) 0.2 (.125*) 0.12 (34.16*) .25 (none)
TND_L669 8.054 NOT DONE 120
TND_L669S B 2.06 10 0.031 (259.8*) 3.915 NOT DONE 355
Q461.e2 B 0.53 (3.88*) 1.25 (8*) .25 0.014 (279.57*) NOT DONE 60
Q461.e2 (TA) A .25 .25 15 (1.6*) .25 NOT DONE 125
Q461.e2 (IV) A .25 (NONE) 1 (.25*) 1.0 (.25*) 10.8 (.2.31*) NOT DONE 180
A .25 (NONE) 5.0 (.5*) 0.92 (.27.1*)
*Represents fold-increase in sensitivity of Env-pseudotyped viruses expressing H681 compared to those expressing Y681.
{The minimum DKW motif necessary for 2F5 recognition is absent.
The overall differences in sensitivity of Envs expressing H681 with that of Y681 to sCD4 and 4E10 MAb were significant (P=0.0002 and P=0.008).
TND-L669 and TND_L669S [44] as well as Q461.e2, Q461.e2 (TA) and Q461.e2 (IV) [43] that were earlier reported to enhance sensitivity of HIV-1 to neutralizing antibodies
were tested in parallel. Fold differences in neutralization sensitivities are given in parentheses.
doi:10.1371/journal.pone.0037157.t001
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was done to evaluate if this substitution of highly conserved
tyrosine to histidine at the 681 position (Y681H) results in global
enhancement of neutralization sensitivity to Envs obtained from
unrelated patients and that this effect was not patient specific. For
this, we selected Envs that are refractory to neutralization to the
reagents tested here. Thus, we substituted Y681H in two unrelated
clade C patient-derived Envs (11-3.J3 and 2-3.J7) [46],
Q259ENVd2.17 (clade A), YU2 (clade B) and CRF02_AG-235
(A/G recombinant) and tested Env-pseudoviruses carrying both
H681 and Y681 in different clade backgrounds for their
sensitivities to sCD4, b12, 4E10, 2F5 MAbs and plasma antibodies
in addition to their infectivity in TZM-bl cells. The neutralization
assays were carried in parallel with Env-pseudotyped viruses TND
L669 and TND S669 [44] as well as Q461.e2, Q461.e2 (TA),
Q461.e2 (IV) and Q461.e2 (TAIV) [43] (Table 1) to assess the
Figure 4. Effect of presence of H681 on gp120-CD4 interaction. A. Neutralization sensitivity of Env-pseudotyped viruses to sCD4 was carried
out in TZM-bl cells. Percent neutralization was measured by scoring RLU as indicated on Y-axis at various concentrations of sCD4 plotted on X-axis. B.
Competition between Env-pseudotyped viruses (carrying H681 and Y681) and anti-CD4 MAb QS1420 for binding to cellular CD4. Env pseudotyped
virus was expected to compete with QS1420 to bind with the cellular CD4 on TZM-bl cells for productive infection. Percent infection of Env
pseudotyped virus on Y-axis in presence of various concentration of QS1420 on X-axis was recorded in comparison with infectivity of virus in absence
of QS1420 which was considered as 100%. Percent infectivity was assessed by measuring RLU in a luminometer. The result in the graph is
representative of a single experiment performed in duplicate. The assay was performed at three independent time points using an independent virus
preparation.
doi:10.1371/journal.pone.0037157.g004
Figure 5. Effect of Y681H on relative binding of gp120 with CD4. Cell-based enzyme-linked Immunosorbant assay (CELISA) was carried out
with indicated Envs. The relative binding of (A) CD4-Ig and (B) IgG1b12 to Env trimers expressed on 293T cells was measured as relative luminescence
units (RLU) on Y-axis. pSG3Denv and untransfected 293T cells were taken as negative control.
doi:10.1371/journal.pone.0037157.g005
Y681H Confers Enhanced HIV-1 Neutralization
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Y681H in the context of these published data. As shown in
Table 1, with Y681H substitution, all the Envs conferred increased
sensitivities to sCD4 and 4E10 MAb (P=0.0002 and 0.008
respectively). With respect to MAbs targeting MPER, we found
that the sensitivity of 2-3.J7 and 11-3.J3 was increased by 4.6 and
3.2 fold respectively, whereas the increase in 4E10 sensitivity of
YU2, Q259d2.17 and CRF02-AG235 Envs by over 30, 14 and 30
folds respectively was noticeable (P,0.05 for all comparisons).
Interestingly, Y681H was found to increase 2F5 sensitivity of 11-
3.J3 Env (clade C Env with rare presence of DKW motif in
MPER) by .2-folds, this substitution conferred increased sensi-
tivity of YU2 Env by 14-folds (P=0.002); however presence of
H681 in both Q259d2.17 and CRF02-AG235 Envs was not found
to alter 2F5 sensitivities. All the Envs expressing H681,except 4.J2
and 11-3.J3, showed significantly greater sensitivity to b12 MAb
than previously reported [43,44]. The clade C Env, 2-3.J7, which
we found sensitive to b12 MAb amongst several Indian clade C
Envs obtained from recent infection showed a 8.8-fold increase in
its sensitivity to b12 with the incorporation of H681. Similarly,
H681 enhanced b12 sensitivity in Q259d217 (.4-folds), YU2
(.14 folds) and CRF02_AG-235 (.30-folds) (Table 1; P,0.05 for
all comparisons). Besides, all the Envs bearing H681 showed
enhanced sensitivity to sCD4 (between 4–125 folds). The
remarkable modulation of CD4bs in all the Envs due to the
presence of H681 resulting in significant enhancement of the
sensitivity to b12 MAb and sCD4 was in contrast to any single
amino acid change such as L669S [44], Q461.e2 (TA) and
Q461.e2 (IV) [43] reported earlier, which resulted in marginal
increment in CD4bs modulation.
Effect of Y681H on gp120 shedding
The possibility of Y681H substitution to reduce the subunit
(gp120 and gp41) association on the viral membrane and
spontaneous shedding of gp120 from the Env trimer was also
considered and examined to explain its contribution in neutral-
ization. To test this, we selected 4.J2, 4.J2 (H681Y), YU2 and YU2
(Y681H) and JRFL as control. We examined both CD4-induced
shedding as well as spontaneous shedding with respect of time.
Cell free viral variants were first quantitated by p24 antigen
ELISA and normalized for quantitative assessment of dissociated
gp120 in Western blot analysis. To test CD4-incuded gp120
Figure 6. Infectivity of Env-pseudotyped viruses in cells expressing low CD4. Infectivity of Env-pseudotyped viruses was tested in (A) HeLa
cells expressing low CD4 (RC49) [48]and (B) monocyte-derived macrophages (MDM). In both cases, effector cells were infected with Env-pseudotyped
viruses with equal infectious units and the infectivity was assessed by immunostaining intracellular p24 and expressed as focus forming units (FFU)
on Y-axis in a b-galactosidase assay as described earlier [46,51]. (C). The b-galactosidase positive cells (in blue) representing MDM (from one donor)
expressing intracellular p24 were scored as focus forming units (FFU) to assess the relative infectivity. For MDM assays, macrophage tropic pNLAD8
was used as positive. In HeLa (RC49) cells, YU2 and JR-CSF were used as controls.
doi:10.1371/journal.pone.0037157.g006
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concentrations of sCD4 and VRC01 MAb at 72 hours; cell
supernatants were collected subsequently and run in 8% SDS-
PAGE as described by Li et al [55]. As shown in Figure 7A, the
shedding induced by sCD4 at various concentrations of sCD4 was
found to be comparable between Envs expressing Y681 and H681.
VRC01 MAb was taken as a negative control inducer of gp120
shedding as recently shown by Li et al. [55]. Furthermore, to
evaluate time-dependent spontaneous gp120 shedding, we exam-
ined loss of infectivity and virus particle-associated gp120 and p24.
Thus, cell supernatants containing Env-pseudotyped viruses were
incubated at 37uC for different indicated times and while
infectivity was assessed in TZM-bl cells, p24 was measured by
ELISA. Virus containing supernatants collected at indicated times
were pelleted in an ultracentrifuge and gp120 and p24 resolved in
10% SDS-PAGE under denaturing conditions. As shown in
Figure 7B, the shedding of gp120 with respect to time was found to
be comparable between Env-pseudotyped viruses expressing H681
and Y681. Thus, our data indicated that the Y681H substitution
had no impact on the association of gp120 and gp41 subunits in
the Env trimers and did not contribute to the increased
neutralization sensitivity.
Frequency of tyrosine to histidine substitution at position
681 in HIV database
We compared the Env sequences in HIV database (www.hiv.
lanl.gov) to examine the frequency of substitution of conserved
tyrosine at position 681. We found that .99% (6/2230 do not
contain Y681) sequences in HIV database have tyrosine at
position 681. Interestingly, H681 was found in two Envs including
4.J2 that were of Indian origin, while other three Envs was found
to contain C681 or S681 (www.hiv.lanl.gov/content/sequence/
EPILIGN/EPI.html). When compared between all the Env clones
from this patient at different time points, except 4.J2, all of the Env
variants contained Y681. Notably, we obtained 10 additional Env
clones containing Y681 from the baseline visit from which 4.J2,
4.J22 and 4.J27 [46] Env clones were obtained; however all of
them turned either non-functional or yielded unacceptable
infectivity titers and therefore not included in any neutralization
assays. Nonetheless, as shown by Kulkarni et al [56], one HIV-1
clade C Env clone (HIV-16845-2.22) obtained from an acutely
infected Indian patient before seroconversion was found to contain
histidine at position 681 (H681) but serine at position 668 (S668)
and showed high sensitivity to both sCD4 and 4E10 MAb (IC50 of
1.0 and 0.1 mg/ml respectively). This suggested that H681, despite
Figure 7. gp120 shedding assay. (A) The CD4-induced gp120 shedding assay was done by Western blot analysis of Envs obtained from
supernatants of 293T cells transfected with the plasmid DNA encoding 4.J2 and YU2 Env variants as well as JRFL Env. HIV-1 gp120 shedding upon
binding of sCD4 and VRC01 from the Env trimers on the surface of 293T cells was assessed by probing with the anti-gp120 human monoclonal
antibodies (VRC01, 447-52D, 3074). (B). gp120 shedding of viral variants with respect to time. Env-pseudotyped viruses harvested from transfected
293T cells were incubated for indicated times at 37uC. The particle associated gp120 shedding was assessed by calculating the ratio of infectivity in
TZM-bl cells and p24 (left panel) and ratio of band intensities of gp120 and p24 by densitometric analysis (right panel).
doi:10.1371/journal.pone.0037157.g007
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introduced due to PCR error.
Discussion
In the present study, we have identified a HIV-1 clade C Env
variant with histidine in place of much conserved tyrosine at
position 681 in gp41 MPER from a recently infected HIV-1
positive Indian patient that showed enhanced sensitivity to
autologous and heterologous plasma antibodies. Subsequent
investigation showed that 4.J2 wild type Env containing H681
exposed conserved neutralizing epitopes both in MPER and
CD4bs in viral envelope and displayed proportionate enhance-
ment of Env sensitivity to 4E10 and sCD4. Previous studies by
Brunel et al [57] has shown that elongated MPER peptide up to
the transmembrane domain (residue 683) increased 4E10 binding
by fourfold as compared to shorter version (671–680). However,
Y681A substitution in a MPER peptide did not improve the 4E10
binding indicating that Y681 or A681 did not contribute in
antibody binding or this substitution did not impact the local
structure relevant for neutralization. Later, similar finding was
reported by Nelson et al [58] and Montero et al [59] about the
binding of MPER directed antibodies to the series of alanine
mutants of MPER peptides which suggest that the structure or
conformation of MPER is not influenced by Y681A. Unlike
Y681A substitution which reduces the MPER specific antibody
binding (Montero et al [59]), Y681H substantially increased
neutralization sensitivity to 4E10 in 4.J2. When H681 was
transferred to unrelated Env clones with different genetic
background and clades replacing the conserved Y681 the
sensitivity of these Envs was found to enhance by several folds to
MAbs targeting MPER and CD4bs, plasma antibodies as well as
sCD4 which suggests that Y681H substitution influences the Env
conformation so as to expose the NAb epitopes in both CD4bs in
gp120 and MPER in gp41 that are otherwise hidden or
insufficiently exposed to immune system. Previous studies that
showed effect of gp41 mutations on both MPER and CDbs
[43,44] demonstrated greater effects on MPER epitopes than that
a single amino acid change could impose on CD4bs. In our study,
we found that Y681H enhanced sensitivity of Envs from distinct
genetic background proportionately to antibodies targeting MPER
and CD4bs as well as sCD4 and was higher in its magnitude
particularly to b12 and sCD4 in contrast to those reported earlier
[43,44]. In addition to H681, we found N668S substitution in
MPER also modulates Env sensitivity to sCD4; however was not
found to affect Env sensitivity to plasma antibodies and 4E10.
Back et al [60] demonstrated that although the same N668S
increased Env sensitivity to sCD4, Env sensitivity to plasma
antibodies was decreased. Our data also support this observation.
The presence of H681 in 4.J2 Env is unique compared to all the
other Envs obtained either at the baseline or at subsequent time
points from this particular patient [46], wherein all the Envs was
found to bear much conserved Y681. This indicates that either
H681 was a minor sporadically generated or it could be a
transmitted virus exposing multiple epitopes as viruses in the early
infection are not selected on the basis of antibody resistance but
possibly on the basis of receptor and coreceptor affinity [61,62]. A
HIV-1 Env clone amplified from acutely infected Indian patient
before seroconversion (HIV-16845-2.22) containing H681 has
recently been reported [56] which also showed enhanced
sensitivity to sCD4 and 4E10, indicating that 4.J2 Env containing
H681 possibly represented the early stage strain though we did not
find this Env to be less glycosylated which is usually a
characteristic feature of early transmitted strains and therefore
demand more focused study and analysis to come to such
conclusion[63]. Although Shen et al [44] demonstrated the basis
for increased exposure of neutralizing epitopes in MPER by a
single L669S substitution; the basis for enhanced Env sensitivity to
reagents interfering gp120-CD4 interaction such as sCD4 and
IgG1b12 was less clear. In the present study, we found that H681
conferred exposure of CD4bs that resulted in increased infection
in HeLa cells and macrophages both expressing low cell surface
CD4. These observations indicated that the CD4bs on the HIV-1
envelope was modulated by a single amino acid change in a distant
gp41 MPER thereby enhancing the capacity of 4.J2 expressing
H681 to infect monocyte-derived macrophages. This observation
was further strengthened when we found that the expression of
H681 rendered Envs to over compete anti-CD4 MAb- QS1420
for relatively rapid engagement with cellular CD4 as opposed to
Y681 suggesting that H681 enhances Env binding to CD4. The
infectivity in low CD4 expressing cells such as macrophages often
correlates with the sensitivity to reagents that block Env:CD4
interaction suggesting a common determinants are involved to
confer these phenotypes [52,64]. Moreover, the enhanced
neutralization sensitivity of H681 variants was not explained by
the dissociation of gp120 from Env trimers as ‘‘shedding’’ effect
because the gp120 dissociation was found similar for both Y681
and H681 variants of the corresponding Envs by either sCD4 or
by spontaneous time dependent shedding. Taken together, the
results suggest that the enhanced neutralization of Y681H mutants
is primarily due to altered antigenic property of Env at the local
site MPER as well as distal CD4 binding site.
Tyrosine (Y681) residue lies in LWYIK motif which is highly
conserved and located immediately proximal to membrane
spanning domain. Previous studies by Chen et al [65] have shown
that deletion of this entire motif or YI (681–682) or IK (682–683)
residues within this motif drastically reduced the membrane fusion
and one-cycle viral replication but retained the Env incorporation
onto the virus particles. It is possible that any change in this highly
conserved motif likely would alter exposition of structural epitopes
during fusion process. Previous studies have also described K683 is
the N-terminal border of trans-membrane domain (TM) and
LWYIK which contains Y681 is pre-TM helical segment
[59,65,66,67,68,69,70]. Pre-TM region participates in formation
and expansion of fusion pores [65,68] and it is thought that this
sequence specifically interact with cholesterol containing mem-
branes as described by Saez-Cirion et al [71] and destabilize the
membrane architecture around the anchoring transmembrane
stalk of gp41. It is likely that Y681H substitution in part altered the
property of Pre-TM and due to which the efficiency of formation
and/or expansion of the fusion pore is reduced although end point
infectivity of the viruses were not reduced (P=0.324) (Figure S3).
The structural changes in Pre-TM during the fusion process or the
kinetics thereof might be altered due to Y681H substitution and
likely modulated the 4E10 access and binding to the neutralization
competent structure (NCS) in gp41 [59]. In addition to enhanced
neutralization sensitivity to antibodies targeting MPER, H681 also
increased Env sensitivity to enfuvirtide (T-20) which inhibits 6-
helix bundle formation, supports the view that this substitution has
affected virus fusion with the target cell membrane. This is in
agreement with the observation by Shen et al [44], where they
reasoned that increased sensitivity to T20 or MPER antibodies
was due to prolonged exposure of MPER due to L669S mutation
that they found. The formation of the pre-hairpin fusion
intermediate following CD4 and coreceptor attachment of the
viral envelope is characterized by the exposure of the N-terminal
hydrophobic fusion domain and the C-terminal MPER of gp41,
which are normally folded inside the gp41 trimers and not exposed
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to the antibodies during fusion. In the present study, we found
significant increase in the T-20 sensitivity of Envs containing
H681in different genetic backgrounds. Time course of 4E10
mediated neutralization of these Env versions along with L669S
Env showed that structural intermediates recognizable by 4E10
existed until 6 min for H681 as opposed to 1 min for Y681,
suggesting the enhanced sensitivity due to H681 was ascribed to
differential exposure of MPER. Increased sensitivity to T-20 and
neutralization of H681 Env pseudotyped virus (pre-adsorbed on
cells) by 4E10 suggests enhanced exposure of MPER, however,
this conclusion can better be drawn from the kinetics of antibody
binding experiments that measure the rate of antibody binding or
dissociation which is the major caveat of this study. Therefore, we
conclude from the available body of data obtained in this study
that single amino acid substitution Y681H leads to enhanced
neutralization sensitivity to MPER directed antibodies as well as
the antibodies to CD4bs. Studies by Sun et al [73] and Song et al
[74] demonstrated that Y681 is buried into the membrane bilayers
and N-terminal portion recognized by MPER specific MAbs has a
kinked structure which maintains the hinge-related function of
MPER. Also the data from Yue et al [67] and Montero et al [59]
suggests that the transmembrane region starts even before than the
684 (which is the start of transmembrane domain according to the
conventional classification) It is likely that Y681H substitution
reduces the membrane immersion depth of this region pulling it
outward or the movement of the local region modulating the
exposure of epitopes for recognition by 2F5 and 4E10 MAbs
during the structural transitions in fusion process.
Owing to the unavailability of crystal structure that include both
the subunits of envelope protein together, it is difficult to know
how a substitution in MPER region of gp41 affects the structural
features at distant sites and modulate anti gp120 antibody binding
and neutralization sensitivity. Although we do not know the
antibody specificity in plasma pool that we tested in this study, it is
likely that a portion of the antibodies was directed to gp120
protein [75]. Although Y681H substitution was found to expose
CD4bs which harbors epitope for b12 MAb in addition to sCD4,
Env clones such as 4.J2 and 11-3.J3 are refractory to b12
neutralization [46], indicating that b12 epitope is too mutated to
be sampled by antibody in these envelopes [76].While the
conformational changes plausibly explain the enhanced antibody
binding and Env sensitivity to the plasma antibodies, b12 MAb
and sCD4, it underscores the need for the detailed structural
analyses to precisely dissect the basis for such phenotype.
Identification of novel motifs in Env capable of enhancing
neutralization potential of HIV-1 would contribute valuable
information to the existing neutralization signatures [4] that might
help in designing strategies for developing vaccine capable of
inducing broadly neutralizing antibodies.
Materials and Methods
Ethics statement
Ethical clearance of this study was specifically obtained from the
National AIDS Research Institute (NARI) Institutional Review
Board (IRB) prior to initiation of the study. Written informed
consent was taken from participants involved in this study.
Autologous plasma and peripheral blood mononuclear cells
(PBMC) of IVC4 patient from which env clones were obtained
was reported previously [46]. Heterologous plasma samples were
obtained from patients during their visit at NARI clinic for routine
testing. PBMCs from HIV negative healthy donors for preparation
of monocytes were obtained following ethical clearance by NARI
IRB.
Patient samples, Env clones and cells
Clade C Env clones (obtained from infected Indian patient) used
in this study were described recently [46]. Ethical clearance of this
study was specifically obtained from the National AIDS Research
Institute (NARI) Institutional Review Board (IRB) prior to
initiation of the study. Written informed consent was taken from
participants involved in this study. Heterologous plasma samples
were obtained from chronically infected patients with CD4 counts
above 450 cells/mm
3 from the National AIDS Research Institute
clinic. Patient samples were obtained with prior approval of
institutional ethics review board (IRB). pSVIIIenv-YU2 and
pSVIIIenv JRCSF plasmids were kindly provided by Dr Paul
Clapham, UMASS Medical School, Worcester, Massachusetts,
USA. Engineered HeLa cells (RC49 clone) were kindly provided
by Dr David Kabat, University of Oregon, Portland, USA. L669
and S669 plasmids [44] were kindly provided by Dr Georgia
Tomaras, Duke University, Durham while Q461.e2, Q461.e2
(TA), Q461.e2 (IV and Q461.e2 (TAIV) [43] were kindly provided
by Dr Julie Overbaugh, University of Washington, Seattle.
Q259ENVd2.17, CRF02AG235 Env clones and pNL-AD8
[77]were obtained through NIH AIDS Research Reagents and
Reference Program, Division of AIDS, NIAID, NIH from Dr Julie
Overbaugh and Drs. Ellenberger, D., Li, B., Callahan, M., and
Butera, S respectively.
Construction of envelope chimera, mutagenesis and
cloning
Env clones were amplified from patient’s peripheral blood
mononuclear cell (PBMC) without culture as described before
[46]. Chimeric envelopes were made by swapping V1V2 by using
HindIII and BbvCI and gp41 fragments using BbvCI and NotI
between sensitive and resistant Envs as shown in Figure 1. Single
point mutations were introduced by site-directed mutagenesis
using the In-Fusion Dry-Down PCR Cloning kit (Clontech Inc.)
following manufacturer’s protocol. Briefly, specific substitutions
were introduced by PCR using high fidelity proof reading
polymerase (Platinum Taq, Invitrogen Inc.); subsequently, single
stranded overhangs were created in amplicons by exonuclease
activity of pox DNA polymerase provided in the kit. These
fragments were then annealed with each other at 37uC and
transformed to E.coli Top10 cells (Invitrogen Inc.). Chimeric and
mutant version of the Envs was confirmed by sequencing.
Pseudovirion preparation and measurement of virus titer
Pseudotyped viruses carrying patient envelope genes were
produced by cotransfection of Env
+ pcDNA 3.1/V5-His-TOPO
with Env-defective HIV-1 backbone vector (pSG3DEnv) [16] into
293T cells (obtained from American Type Culture Collection;
ATCC) during log growth phase in 6-well tissue culture trays
(Corning Inc) using calcium phosphate (Promega Inc) following
manufacturer’s protocol. Cell supernatants carrying progeny
pseudotyped viruses were harvested at 48 hours post-transfection,
and stored at 280uC until further usage. The infectivity assays
were done in TZM-bl cells in 96-well microtiter plate and
infectivity titers determined by measuring the luciferase activity
respectively as described elsewhere [78].
Preparation of monocyte derived macrophages
Monocyte-derived macrophages were prepared from peripheral
blood mononuclear cells (PBMCs) from healthy donors followed
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Institutional Review Board. Briefly, PBMCs were separated by
using Ficoll gradient and were carefully collected from the buffy
coat ring and were washed in RPMI-1640 to remove impurities.
Monocytes were prepared from PBMCs using Dynabeads MyPure
Monocyte Kit 2 (Invitrogen Inc.) following manufacturer’s
protocol. Monocytes were plated in T75 tissue culture flask
(Corning Inc.) in presence of Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine sera (FBS) and
100 ng/ml of macrophage-colony stimulating factor (M-CSF)
(Sigma Inc.) and incubated at 37uCi naC O 2 incubator. The non-
adherent cells were removed the following day and adhered cells
were further incubated for 5–7 days for differentiation. Macro-
phages were gently removed with the help of Versene (Invitrogen
Inc.), and scrapping with cell scrapper, washed with DMEM and
2610
4 cells were plated in 96-well tissue culture tray and further
incubated for overnight at 37 C in a CO2 incubator. Macrophages
were infected with Env-pseudotyped viruses by spinoculation as
described previously [79,80]. In addition, commercially available
monocytes (obtained commercially from Lonza Inc.) were also
used to prepare macrophages following manufacturer’s protocol.
In all cases, monocytes were allowed to adhere in plastic plates and
were incubated with M-CSF as described above for differentiation
to macrophages.
Neutralization assays
Neutralization assays were done by measuring reduction in
luciferase activity in a single round infection of TZM-bl cells with
Env-pseudotyped viruses as described earlier [46]. Antibody titers
were calculated as the inhibitory concentration (IC50) for MAbs
and reciprocal dilution (ID50) for plasma causing 50% reduction of
relative light units measured in a luminometer (Perkin Elmer Inc.)
Time Course of 4E10 Neutralization Assay
The time course of neutralization of Envs by 4E10 MAb was
determined in a synchronized post-attachment HIV-1 pseudo-
typed virus neutralization assay as described earlier [44]. Briefly,
TZM-bl cells (1610
4/well) were plated and allowed to adhere
overnight. The plate was then cooled on ice for 15 minutes
followed by addition of cold Env pseudotyped viruses. Virus was
allowed to adhere on cells for 2 hours on ice. To remove unbound
viruses, plates were washed with fresh, cold medium. Warm
medium (150 ml/well) was added to each well followed by 100 ml
of inhibitory concentrations of 4E10 MAb (10 mg/ml) at different
time intervals (0, 5, 10, 15, 20, 25, 30 and 60 min). Infectivity was
measured by relative light units (RLUs) as described above at
48 hours.
Env-anti CD4 competition assay
The competition for binding of anti-CD4 MAb and Env-
pseudotyped viruses to cellular CD4 was carried out in TZM-bl
cells. For this, mouse monoclonal antibody, QS4120 (Calbiochem,
Inc.), which binds to domain 1 of CD4 and blocks binding of
gp120 to CD4 was used. Briefly, QS4120 MAb was serially diluted
(2-fold) in 50 ml of growth medium in a 96-well tissue culture tray
(Corning Inc.). 50 ml pseudotyped virus (containing equal infec-
tious titer) of each Env was then mixed with serially diluted
antibody.100 ml TZM-bl cells were subsequently added onto this
mixture and further incubated for 3 hours in a CO2 incubator at
37uC. Residual viruses were removed gently after 3 hours and
replenished with fresh growth media. The plate was further
incubated for additional 2 days in a CO2 incubator at 37uC. Virus
infectivity was measured as a function of RLU in a luminometer.
gp120 shedding assay
CD4-induced gp120 shedding. The CD4-induced gp120
shedding was examined as described by Li et al. [55]. Briefly, 293T
cells were co-transfected with Env plasmids and pSG3Denv. Forty-
eight hours post transfection, approximately 1610
7 cells were
collected and washed with phosphate buffered saline; PBS
(pH 7.4). Two-hundred-micro liter aliquots of the cell suspension
were taken into micro centrifuge tubes for sCD4 or VRC01 at a
given concentration. The cells in microfuge tubes were spun at
3506g for 5 minutes and a total of 160 ml of the supernatant was
removed and discarded. 10 ml of the ligand solutions were then
added to the cells to make final concentrations as 10 mg/ml, 5 mg/
ml and 1 mg/ml. Cells were mixed and incubated at 37uC for
2 hours with gentle mixing every 20 min. The cells were then
subjected to centrifugation, and the supernatants were transferred
to fresh tubes. A total of 25 ml of each supernatant was resolved in
8% SDS-PAGE. The proteins were transferred to PVDF
membranes for Western blotting. To identify gp120, 1:1 mixture
of VRC01, anti V3 MAbs 447-52D (in case of YU2 and JRFL)
and 1:1 mix of VRC01 and anti-V3 MAb 3074 [81] (in case of
4.J2) was used as a primary antibody, followed by a horseradish
peroxidase (HRP)-conjugated anti-human secondary antibody
(Thermo Scientific, Inc.) and blots were developed with luminol
substrate (Super Signal West Dura kit; Thermo Scientific Inc.).
Time-dependent gp120 shedding. To assess spontaneous
gp120 shedding in a time-dependent manner, 293T cells were co-
transfected with Env plasmids as described above and virus
contining supernatants collected after two days. The culture
supernatants containing Env pseudotyped viruses were filtered
through a 0.45 mm filter to remove any cell debris and
subsequently incubated at 37uC for various times (0, 1, 2, 3, 4,
and 8 h). At each time point, a sample of each virus was collected
and frozen at 280uC. The virus stocks were later thawed together
and tested for single-cycle infectivity in TZM-bl cells and p24 by
ELISA. Virus supernatants incubated for 1, 4 and 8 hours were
further pelleted by ultracentrifugation for 1 hour in presence of
20% sucrose containing 10 mM Tris-Cl (pH 7.4), 100 mM
NaCl,1 mM EDTA at 35,0006ga t4 uC [82]. Virus pellets were
dissolved in 30 ml PBS and resolved in 10% SDS-PAGE gel.
gp120 and p24 were developed by Western blotting using HIV+
patient sera pool (1:100). The relative levels of particle-associated
gp120 were calculated as the ratio of the infectivity in TZM-bl
cells and p24 concentrations and ratio between band intensities
between gp120 and p24 (by densitometry analysis).
Cell-Based Enzyme-Linked Immunosorbant Assay
(CELISA)
The binding of MAbs to HIV-1 Env trimers expressed on cells
was measured using a cell-based ELISA system, as described by
Haim et al [83] and Wilen et al [84]. Briefly, 293T cells were seeded
in 96-well plates (3610
4 cells/well) and transfected the following
day with 100 ng of Env expressing plasmid and 200 ng of
pSG3DEnv backbone plasmid per well using lipofectamine 2000
(Invitrogen Inc). Three days later, the growth medium was
discarded and cells were gently washed with PBS. After washing
cells were incubated with IgG1b12 or CD4-Ig in blocking buffer
(35 mg/ml BSA, 10 mg/ml non-fat dry milk, 1.8 mM CaCl2,
1 mM MgCl2,25 mM Tris, pH 7.5 and 140 mM NaCl) for one
hour at room temperature. Cells were then washed four times with
blocking buffer and four times with washing buffer (140 mM
NaCl, 1.8 mM CaCl2, 1 mM MgCl2 and 20 mM Tris, pH 7.5).
A horseradish peroxidase (HRP)-conjugated antibody specific for
the Fc region of human IgG was then incubated with the samples
for 45 minutes at room temperature. Cells were washed five times
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enzyme activity was determined after the addition of 40 ml of 1:1
mix of Western lightning oxidizing and luminol reagents (Thermo
Scientific Inc.). Binding of IgG1b12 or CD4-Ig was measured as a
function of light emission (relative luminescence units) in a
luminometer (Victor 4, Perkin Elmer Inc).
Statistical analysis
Statistical analyses were performed using Graph Pad prism
(version 5.1). To calculate the statistical significance (P values)
between the ligand binding to H681 and Y681 variants of Envs in
CELISA assay, we took more than five values (RLU) for each Env
and significance of difference between the medians was calculated
by paired t test. The multiple values for each Env were obtained
from independent assays done in triplicates. P value less than 0.05
was considered significant. Similar tests were also applied to
calculate P values for the difference in macrophage infectivity of
H681 and Y681 Env variants. For assessing the differences in the
sensitivities of Env-pseudotyped viruses to T20 and 17b, we used
IC50 values for each Env pair (H681 and Y681) obtained from at
least three independent assays and applied paired t test to examine
whether mean IC50 values were significant. Spearman’s rank
correlation was applied to evaluate the correlation between the
Env sensitivity to 4E10 and their infectivity to TZM-bl cells. For
this, average IC50 values of 4E10 and average percent infectivity
of H681 variants to Y681 variants of Envs were used.
Supporting Information
Figure S1 Effect of Y681H substitution on degree of
inhibition of Env-pseudotyped viruses by T20. The
percent reduction in infectivity of each virus indicated on Y-axis
at various dilutions of T20 indicated on X-axis in TZM-bl cells
were assessed by measuring the reduction in relative luminescence
units (RLU) in a luminometer. Experiments were done in
duplicates and repeated at least three times. Note that Envs
expressing H681 showed increased inhibition by T20 than the
Y681 version of respective Env (P=0.04).
(TIF)
Figure S2 Effect of Y681H substitution on exposure of
CD4-induced epitopes. The effect of Y681H on relative
exposure of coreceptor binding sites was assessed by examining
Env sensitivity to coreceptor mimetic 17b MAb. The percent
inhibition in infectivity of Env-pseudotyped viruses in TZM-bl
cells indicated on Y-axis was assessed by measuring the reduction
in relative luminescence units (RLU) at various concentration of
antibody indicated on X-axis. Experiments were done in
duplicates and repeated at least three times. Note that Env
expressing H681 are more sensitive than Y681 versions suggesting
shift towards CD4-bound-like structure with the coreceptor
binding site more exposed.
(TIF)
Figure S3 Effect of Y681H on infectivity of Env-pseudo-
typed viruses in TZM-bl cells. Effect of Y681H substitution
on infectivity of Env-pseudotyped viruses in different genetic
backgrounds with equal virus particles (p24) was assessed in TZM-
bl cells. TND L669S Env that was shown by Shen et al [44] to
significantly enhance Env sensitivity to neutralizing antibodies was
used as control. Percent infection of Y681H mutants or H681Y
mutant (in case of 4.J2) relative to their wild type counterparts is
represented on Y-axis.
(TIF)
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